Adaptive Biotechnologies paid its one named executive on file $1.7M in FY2024 (Dec).
Pay$100 in the stock at the end of FY20 → $8
Pay of each named executive
Chad RobinsChief Executive Officer and Chairman
| FY2023 (Dec) | |||||||
| FY2022 (Dec) | Not disclosed | ||||||
| FY2021 (Dec) | Not disclosed |
3 years
Harlan Robins, PhDChief Scientific Officer
| FY2022 (Dec) | Not disclosed | ||||||
| FY2021 (Dec) | Not disclosed |
2 years
Julie RubinsteinPresident and Chief Operating Officer
| FY2023 (Dec) | |||||||
| FY2022 (Dec) | Not disclosed | ||||||
| FY2021 (Dec) | Not disclosed |
3 years
Susan BobulskyChief Commercial Officer, MRD
| FY2024 (Dec) | Not disclosed | ||||||
| FY2023 (Dec) | Not disclosed |
2 years
Kyle PiskelChief Financial Officer
| FY2023 (Dec) | Not disclosed | ||||||
| FY2022 (Dec) | Not disclosed |
2 years
CEO pay against the pay peers
In FY2025 (Dec), the median CEO pay of the 4 peers with pay on file was $12.3M. The CEO of Adaptive Biotechnologies was paid $9.1M, 26% below the median.
- 1Natera
- 2Twist Bioscience
- 3Immunocore Holdings
- 4Adaptive BiotechnologiesThis company
- 5Veracyte
- 6Allogene Therapeutics, Inc.Not disclosed
- 7CareDx, Inc.Not disclosed
- 8Castle Biosciences, Inc.Not disclosed
- 9Codexis, Inc.Not disclosed
- 10Fulgent Genetics, Inc.Not disclosed
- 11Guardant HealthNot disclosed
- 12Maravai LifeSciences Holdings, Inc.Not disclosed
- 13Mesa Laboratories, Inc.Not disclosed
- 14Myriad Genetics, Inc.Not disclosed
- 15NeoGenomics, Inc.Not disclosed
- 16Pacific Biosciences of California, Inc.Not disclosed
- 17Quanterix CorporationNot disclosed
- 18Recursion PharmaceuticalsNot disclosed
- 19Sage Therapeutics, Inc.Not disclosed
- 20Voyager Therapeutics, Inc.Not disclosed
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.